Research and Markets: United Arab Emirates Pharmaceuticals and Healthcare Report Q3 2011 - UAE is Building Multiple Health

DUBLIN--(BUSINESS WIRE)-- Research and Markets( has announced the addition of the "United Arab Emirates Pharmaceuticals and Healthcare Report Q3 2011" report to their offering.

In 2010, the UAE pharmaceutical market reached a value of AED5.71bn (US$1.56bn). One of the key drivers of growth for the UAE pharmaceutical market is increased health expenditure. BMI expects that most of the value development will be realised in the prescription sector, boosted by rising population numbers and a changing diseases profile. In particular, the country is tackling an obesity and diabetes epidemic, which will also require long-term treatment of related conditions, such as increased blood pressure. The recently established single market of the six GCC states (Saudi Arabia, Oman, Qatar, Bahrain, the UAE and Kuwait) will also facilitate the placement of foreign products in the region.

Headline Expenditure Projections

  • Pharmaceuticals: AED5.71bn (US$1.56bn) in 2010 to AED6.13bn (US$1.67bn) in 2011; +7.3% in local currency terms and +7.3% in US dollar terms. Forecast up moderately from Q211 due to macroeconomic factors.
  • Healthcare: AED32.93bn (US$8.97bn) in 2010 to AED36.16bn (US$9.85bn) in 2011; +9.8% in local currency terms and +9.8% in US dollar terms. Forecast unchanged from Q211.
  • Medical devices: AED2.93bn (US$797mn) in 2010 to AED3.25bn (US$886mn) in 2011; +11.1% in local currency terms and +11.1% in US dollar terms. Forecast up marginally from Q211 due to analyst modification.

Key Trends & Developments

  • Provisional data issued by the World Intellectual Property Organisation (WIPO) has revealed that, international patent filings by Gulf countries under WIPO's Patent Cooperation Treaty rose 14.56% to 118 in 2010, compared to 103 in 2009 and despite troubled economic conditions. Saudi Arabia had the most patent filings with 78, followed by the UAE with 29, Qatar with seven, and Oman with four; while Kuwait and Bahrain failed to register any patent filings last year.
  • In March 2011, the Ministry of Health announced that the price of drugs used for treating chronic diseases will be reduced by up to 15%. The costs of 177 types of medicines in the UAE are currently much higher than in other countries in the region. In the UAE, a large section of the population suffers from chronic ailments such as Type 2 diabetes and cardiovascular diseases.
  • Figures published by the Beat Obesity Campaign' have revealed that over 32% of schoolchildren in Dubai are overweight or obese. Meanwhile, a study conducted by the UAE Ministry of Health, the Centre for Disease Control in the US, and the World Health Organization has revealed that as per 2010 statistics, 54.7% of children living in the UAE between the ages of six and 16 were classed in the overweight and obese category. In 2009, however, the figure was 26%.
  • Elsewhere, the Abu Dhabi Health Services Company announced that it had begun construction work on the new Mafraq Hospital, estimated at a cost AED2.2bn (US$598mn). The new Mafraq premises will be located adjacent to the existing Mafraq facility in Abu Dhabi. The new hospital, which will contain 739 beds and provide 139 outpatient clinics, will also serve as a centre of excellence in thoracic and orthopaedic surgery, and burns treatment within the Emirate.

Companies Mentioned:

  • Gulf Pharmaceutical Industries (Julphar)
  • Globalpharma
  • Modern Pharmaceutical Company (MPC)
  • Neopharma
  • Medpharma
  • GlaxoSmithKline (GSK)
  • Pfizer
  • Novartis
  • Johnson & Johnson (J&J)
  • Sanofi-Aventis
  • Abbott Laboratories
  • Merck & Co

For more information visit


Research and Markets
Laura Wood, Senior Manager,
[email protected]
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

KEYWORDS:   United Arab Emirates  Middle East

INDUSTRY KEYWORDS:   Health  Hospitals  Pharmaceutical